1618-47-9

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Iodo-6-Methylpyridazine is used as a building block for the development of various pharmaceuticals, contributing to the creation of new drugs with potential therapeutic applications. Its unique structure allows for the formation of diverse chemical entities that can target specific biological pathways.
Used in Agrochemical Development:
In the agrochemical industry, 3-Iodo-6-Methylpyridazine is utilized as a key intermediate in the synthesis of pesticides and other crop protection agents. Its incorporation into these compounds can enhance their effectiveness in controlling pests and diseases, thereby improving crop yields and quality.
Used in Organic Synthesis as a Reagent:
3-Iodo-6-Methylpyridazine serves as a valuable reagent in organic synthesis, facilitating the formation of complex organic molecules. Its presence in reactions can lead to the production of desired products with high yields and selectivity, making it an essential component in many synthetic routes.
Used in Chemical Research:
As a compound of interest in chemical research, 3-Iodo-6-Methylpyridazine is employed to study various aspects of chemistry, such as reaction mechanisms, structural properties, and the development of new synthetic methodologies. Its unique features make it a useful probe for understanding fundamental chemical processes.
Used in Coordination Chemistry for Ligand Preparation:
3-Iodo-6-Methylpyridazine is used as a precursor in the preparation of ligands for coordination chemistry. These ligands can bind to metal centers, forming coordination complexes with potential applications in catalysis, materials science, and other areas.
Used in Organometallic Reactions as a Catalyst Component:
In organometallic chemistry, 3-Iodo-6-Methylpyridazine can be incorporated into catalyst systems, enhancing their performance in various chemical transformations. Its presence in these catalysts can improve reaction rates, selectivity, and overall efficiency, making it a valuable component in organometallic catalysis.

Upstream product

• 1121-79-5 3-chloro-6-methylpyridazine 

Downstream Products

• 77778-18-8 3-(3-hydroxy-1-propynyl)-6-methylpyridazine 
• 68321-49-3 6-methyl-3-phenylethynylpyridazine 
• 68321-55-1 6-Methyl-3-phenylethynyl-pyridazine 1-oxide 
• 68031-32-3 6-methyl-3-phenethyl-6-pyridazine 
• 1108741-09-8 diethyl ({(3,5-dichloro-phenylsulphonyl)-[1-(6-methyl-pyridazin-3-yl)-1H-indol-5-yl]-amino}-methyl)-phosphonate 
• 1173897-84-1 3-methyl-6-(trifluoromethyl)pyridazine 
• 1233845-66-3 1,4-bis((6-methylpyridazin-3-yl)ethynyl)-2,5-dioctyloxybenzene 
• 1405128-13-3 3-methyl-6-(pyridin-2-yl)pyridazine 
• 1405128-81-5 tert-butyl ((3S)-1-(3-((2-(2,6-difluorophenyl)-imidazo[1,5-b]pyridazin-7-yl)amino)-4-pyridinyl)-3-piperidinyl)carbamate 
• 1405128-82-6 tert-butyl 4-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)-4-pyridinyl)-1-piperazinecarboxylate 
• 1405126-16-0 2-(2,6-difluorophenyl)-N-(4-(1-piperazinyl)-3-pyridinyl)imidazo[1,5-b]pyridazin-7-amine 
• 1405128-85-9 tert-butyl ((3R,4R,5S)-4-((tert-butyl(dimethyl)silyl)oxy)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)-4-pyridinyl)-5-methyl-3-piperidinyl)carbamate 
• 1405126-39-7 (3R,4R,5S)-3-amino-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)-4-pyridinyl)-5-methyl-4-piperidinol 
• 1405128-86-0 N-(4-chloro-3-pyridinyl)-2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-amine 

Relevant academic research and scientific papers

Synthesis of Triptycene-Based Molecular Rotors for Langmuir-Blodgett Monolayers

We describe syntheses of six triptycene-containing molecular rotors with several single-crystal X-ray diffraction analyses. These rod-shaped molecules carrying an axial rotator are designed to interleave on an aqueous surface into Langmuir-Blodgett (LB) monolayers containing a two-dimensional trigonal array of dipoles rotatable about an axis normal to the surface. Monolayer formation was verified with the simplest of the rotor structures. On an aqueous subphase containing divalent cations (Mg2+, Ca2+, Zn2+, Sr2+, or Cd2+), the LB isotherm yielded an area of 53 ± 3 ?2/molecule (monolayer of type A), compatible with the anticipated triangular packing of axes normal to the surface. On pure water, the area is 30 ± 3 ?2/molecule, and it is proposed that in this monolayer (type B), the molecular axes are tilted by 40-45° to a structure similar to those observed in single crystals of related triptycenes. After transfer to a gold surface, ellipsometry and PM IRRAS yield tilt angles of 29 ± 4° (monolayers of type A) and 38 ± 4° (type B). A full-scale examination of monolayers from all the rotors on a subphase and after transfer is underway and will be reported separately.

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors

High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit (rac-1) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound 22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50values of 0.024?nM and 0.095?nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50?=?28?nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound 22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is i

BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS

The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS

The present invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.

Aryl-4-ethynyl-isoxazole derivatives

The present invention is concerned with aryl-4-ethynyl-isoxazole derivatives of formula I wherein R1 to R5 are as described in the specification and pharmaceutically acceptable salt thereof. This class of compounds has high affinity and selectivity for GABA A α5 receptor binding sites, being useful as a cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.